People · Operator
Named in public records as an officer, director or promoter · active 2012–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ensoma, Inc. | — | Biotechnology | Series D+ | $169.6M | $2.3B | 2022 |
| Invenra Inc. | — | Pharmaceuticals | Series A | $21.3M | $220.8M | 2012 |
Emile Nuwaysir at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Emile Nuwaysir on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 1 | 10 |
| STEPHEN KNIGHT | 1 | 6 |
| Paul Weiss | 1 | 5 |
| David Snyder | 1 | 5 |
| Stan Rose | 1 | 3 |
| KUSH M. PARMAR | 1 | 3 |
| Albert Seymour | 1 | 2 |
| Richard Lesniewski | 1 | 2 |
| Nihal Sinha | 1 | 2 |
| Paula Soteropoulos | 1 | 1 |
| Kouki M Harasaki | 1 | 1 |
| Mark M Chin | 1 | 1 |
| Albert M Seymour | 1 | 1 |
| Roland Green | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.